Welcome to our dedicated page for West Pharm Svcs SEC filings (Ticker: WST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
West Pharmaceutical Services, Inc. filings document the regulatory record of a Pennsylvania operating company that supplies injectable drug containment, delivery and contract-manufacturing services. Its Form 8-K reports commonly furnish quarterly and full-year operating results, financial presentation materials and Regulation FD disclosures tied to earnings releases.
West's proxy and annual meeting filings cover board elections, executive compensation, advisory votes and shareholder voting results for its common stock. Other current reports record executive-transition matters and related governance disclosures, while exhibit filings provide the formal press releases, presentations and Inline XBRL cover-page data attached to those events.
West Pharmaceutical Services reported a strong first quarter of 2026 and raised its full-year outlook. Net sales reached $844.9 million, up 21.0% from a year earlier, with organic growth of 15.3%. Diluted EPS rose to $1.92, a 56.1% increase, and adjusted-diluted EPS climbed 46.9% to $2.13 as margins improved.
Growth was driven by the Proprietary Products segment, particularly High-Value Product components and delivery devices, and by demand tied to GLP‑1 obesity and diabetes treatments. Management now guides 2026 net sales to $3.295–$3.350 billion and adjusted-diluted EPS to $8.40–$8.75, both above previous ranges. During the quarter, the company generated free cash flow of $47.2 million and repurchased 1.2 million shares for $297.6 million.
HAUGEN JANET BRUTSCHEA reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services director Janet Brutschea Haugen received a grant of 52 Phantom Stock Units tied to common stock. The units were valued at $250.64 per unit, bringing her total Phantom Stock Units to about 260.494 held directly.
Footnote disclosures state that Phantom Stock Units will be settled in shares of stock when she terminates service as a director. A separate line shows she directly holds 1,321.258 shares of common stock. Another footnote notes 1,071 restricted stock units and dividend equivalents that vest in full on the date of the next annual shareholder meeting.
The Vanguard Group filed an Amendment to its Schedule 13G/A reporting 0 shares beneficially owned of West Pharmaceutical Services Inc common stock, representing 0% of the class. The filing notes an internal realignment on January 12, 2026 after which certain Vanguard subsidiaries report holdings separately.
West Pharmaceutical Services uses its 2026 proxy to highlight solid 2025 performance and key governance items ahead of the May 4, 2026 virtual annual meeting. Net sales reached $3.1B, up 6.3%, with organic growth of 4.3%. Reported-diluted EPS was $6.79 and adjusted-diluted EPS was $7.29, up 8%, while operating cash flow was $755M and free cash flow $469M, up 70%.
The Board proposes re-electing eleven directors, an annual advisory Say‑on‑Pay vote, ratification of the auditor, and opposes a shareholder proposal for an independent Board chair. The company emphasizes majority‑independent Board oversight, strong risk and cybersecurity frameworks, long‑running dividend growth, and a pay program heavily tied to performance, which received over 94% support in the 2025 Say‑on‑Pay vote. The proxy also notes CEO Eric Green’s intention to retire once a successor is hired in the second half of 2026.
West Pharmaceutical Services, Inc. announced that Eric M. Green, its President, Chief Executive Officer and Chair of the Board, plans to retire from all three roles once a successor is hired to support a smooth leadership transition.
The Board has engaged a leading executive recruiting firm and expects the transition to occur in the second half of 2026. At the same time, the Company reaffirmed its previously issued 2026 financial guidance from its February 12, 2026 earnings release.
Green has led West as President and CEO since April 2015 and became Chair in May 2022. During his tenure, the Company more than doubled sales, achieved total shareholder return of approximately 350%, and generated $3.07 billion in net sales in fiscal 2025.
West Pharmaceutical Services reported that SVP, General Counsel and Corporate Secretary Norman D. Finch Jr. received equity awards. He was granted 1,285 restricted stock units and 3,057 stock options, each with an exercise right to buy common shares. Both the restricted stock units and options vest in four equal annual installments beginning on March 1, 2027.
Green Eric Mark reported acquisition or exercise transactions in this Form 4 filing.
West Pharmaceutical Services reported that President, CEO and Board Chair Eric Mark Green received new equity awards. On March 1, 2026, he was granted 6,986 restricted stock units, each representing a contingent right to receive one share of WST common stock.
On the same date, he was also granted 16,630 stock options to buy WST common stock. Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, tying the awards to multi‑year service and performance at the company.
Favorite Annette F reported acquisition or exercise transactions in this Form 4 filing.
WEST PHARMACEUTICAL SERVICES INC executive Annette F. Favorite, Sr. VP & Chief HR Officer, reported equity awards rather than open-market trades. She received 720 restricted stock units, each representing one share of WST common stock, and 1,712 stock options, all held directly. Both the restricted stock units and options vest in four equal annual installments beginning on March 1, 2027.
West Pharmaceutical Services senior vice president Shane Alden Campbell reported equity compensation grants consisting of restricted stock units and stock options. He acquired 1,131 restricted stock units, each representing the right to receive one share of West common stock, and 2,691 stock options with a right to buy West shares.
Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, meaning the awards become exercisable or deliverable over time rather than all at once. These are non-cash, equity-based compensation awards and do not reflect any open-market stock purchases or sales.